Plasma-lyte

Plasma-Lyte is a crystalloid solution for intravenous infusion, with varying electrolyte formulation depending on market. Generally the solution has a composition that mimics human physiological plasma electrolyte concentrations, osmolality and pH.[1]

It is manufactured and marketed by Baxter International Inc.[2] and available as a generic medication.[3][4]

Plasma-lyte 148 (pH7.4)

Plasma-Lyte 148 is a market-specific solution available in the United Kingdom and Australia, among others and has the following composition:[5]

  • Sodium 140 mmol/L
  • Potassium 5 mmol/L
  • Magnesium 1.5 mmol/L
  • Chloride 98 mmol/L
  • Acetate 27 mmol/L
  • Gluconate 23 mmol/L

A Plasma-Lyte 148 with 5% glucose is also manufactured by Baxter[6].

References

  1. ↑ 1: Rizoli S. PlasmaLyte. J Trauma. 2011 May;70(5 Suppl):S17-8. doi: 10.1097/TA.0b013e31821a4d89. PMID 21841561.
  2. ↑ 2: Baxter. Plasma-Lyte 148 product information. 2013. available at URL: http://www.baxterhealthcare.com.au/downloads/healthcare_professionals/cmi_pi/plasmalyte148_pi.pdf Archived 23 June 2017 at the Wayback Machine
  3. ↑ "2022 First Generic Drug Approvals". U.S. Food and Drug Administration (FDA). 3 March 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.
  4. ↑ "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.
  5. ↑ "TGA eBS - Product and Consumer Medicine Information Licence". www.ebs.tga.gov.au. Retrieved 10 August 2026.
  6. ↑ "TGA eBS - Product and Consumer Medicine Information Licence". www.ebs.tga.gov.au. Retrieved 10 August 2026.
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.